Search

Your search keyword '"Borchiellini, A."' showing total 1,485 results
Start Over Author "Borchiellini, A."
1,485 results on '"Borchiellini, A."'

1. Feature Selection Techniques for CR Isotope Identification with the AMS-02 Experiment in Space

Author

Borchiellini, Marta, Mano, Leandro, Barão, Fernando, and Vecchi, Manuela

Subjects
Astrophysics - High Energy Astrophysical Phenomena, Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

Isotopic composition measurements of singly charged cosmic rays (CR) provide essential insights into CR transport in the Galaxy. The Alpha Magnetic Spectrometer (AMS-02) can identify singly charged isotopes up to about 10 GeV/n. However, their identification presents challenges due to the small abundance of CR deuterons compared to the proton background. In particular, a high accuracy for the velocity measured by a ring-imaging Cherenkov detector (RICH) is needed to achieve a good isotopic mass separation over a wide range of energies. The velocity measurement with the RICH is particularly challenging for $Z=1$ isotopes due to the low number of photons produced in the Cherenkov rings. This faint signal is easily disrupted by noisy hits leading to a misreconstruction of the particles' ring. Hence, an efficient background reduction process is needed to ensure the quality of the reconstructed Cherenkov rings and provide a correct measurement of the particles' velocity. Machine learning methods, particularly boosted decision trees, are well suited for this task, but their performance relies on the choice of the features needed for their training phase. While physics-driven feature selection methods based on the knowledge of the detector are often used, machine learning algorithms for automated feature selection can provide a helpful alternative that optimises the classification method's performance. We compare five algorithms for selecting the feature samples for RICH background reduction, achieving the best results with the Random Forest method. We also test its performance against the physics-driven selection method, obtaining better results.

Published
2024
Full Text
View/download PDF

2. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Author

Montemagno, Christopher, Jacquel, Arnaud, Pandiani, Charlotte, Rastoin, Olivia, Dawaliby, Rosie, Schmitt, Thomas, Bourgoin, Maxence, Palenzuela, Héliciane, Rossi, Anne-Laure, Ambrosetti, Damien, Durivault, Jerome, Luciano, Frederic, Borchiellini, Delphine, Le Du, Julie, Gonçalves, Leticia Christina Pires, Auberger, Patrick, Benhida, Rachid, Kinget, Lisa, Beuselinck, Benoit, Ronco, Cyril, Pagès, Gilles, and Dufies, Maeva

Published
2024
Full Text
View/download PDF

3. The role of electron capture decay in the precision era of Galactic cosmic-ray data

Author

Borchiellini, M., Maurin, D., and Vecchi, M.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Electron capture (EC) decay relies on attachment and stripping cross-sections, that in turn, depend on the atomic number of the nucleus. We revisit the impact of EC decay in the context of the high-precision cosmic-ray fluxes measured by the AMS-02 experiment. We derive the solution of the steady-state fluxes in a 1D thin disk model including EC decay. We compare our results with relevant elemental and isotopic fluxes and evaluate the impact of this process, given the precision of recent AMS-02, ACE-CRIS, SuperTIGER, and Voyager data. We find this impact to be at the level or larger than the precision of recently collected data for several species, e.g. $_{31}$Ga and $_{33}$As, indicating that EC decay must be properly taken into account in the calculation., Comment: 8 pages, 3 figures, Proceedings for International Cosmic Ray Conference (ICRC) 2023

Published
2023

4. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Author

ODonnell, Peter, Milowsky, Matthew, Petrylak, Daniel, Hoimes, Christopher, Flaig, Thomas, McKay, Rana, Bilen, Mehmet, Srinivas, Sandy, Burgess, Earle, Ramamurthy, Chethan, George, Saby, Geynisman, Daniel, Bracarda, Sergio, Borchiellini, Delphine, Geoffrois, Lionnel, Maroto Rey, Jose, Ferrario, Christiano, Carret, Anne-Sophie, Yu, Yao, Guseva, Maria, Homet Moreno, Blanca, Rosenberg, Jonathan, Moon, Helen, Friedlander, Terence, and Mar, Nataliya

Subjects
Humans, Cisplatin, Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell
Abstract

PURPOSE: Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS: In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms. RESULTS: The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%). CONCLUSION: EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.

Published
2023

5. Feature Selection Techniques for CR Isotope Identification with the AMS-02 Experiment in Space

Author

Marta Borchiellini, Leandro Mano, Fernando Barão, and Manuela Vecchi

Subjects
feature selection, cosmic rays, isotope identification, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Isotopic composition measurements of singly charged cosmic rays (CR) provide essential insights into CR transport in the Galaxy. The Alpha Magnetic Spectrometer (AMS-02) can identify singly charged isotopes up to about 10 GeV/n. However, their identification presents challenges due to the small abundance of CR deuterons compared to the proton background. In particular, a high accuracy for the velocity measured by a ring-imaging Cherenkov detector (RICH) is needed to achieve a good isotopic mass separation over a wide range of energies. The velocity measurement with the RICH is particularly challenging for Z=1 isotopes due to the low number of photons produced in the Cherenkov rings. This faint signal is easily disrupted by noisy hits leading to a misreconstruction of the particles’ ring. Hence, an efficient background reduction process is needed to ensure the quality of the reconstructed Cherenkov rings and provide a correct measurement of the particles’ velocity. Machine learning methods, particularly boosted decision trees, are well suited for this task, but their performance relies on the choice of the features needed for their training phase. While physics-driven feature selection methods based on the knowledge of the detector are often used, machine learning algorithms for automated feature selection can provide a helpful alternative that optimises the classification method’s performance. We compare five algorithms for selecting the feature samples for RICH background reduction, achieving the best results with the Random Forest method. We also test its performance against the physics-driven selection method, obtaining better results.

Published
2024
Full Text
View/download PDF

6. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy

Author

Augusto B. Federici MD, Rita Carlotta Santoro MD, Cristina Santoro MD, Lisa Pieri MD, Roberto Mario Santi MD, Giovanni Barillari MD, Alessandra Borchiellini MD, Alberto Tosetto MD, Ezio Zanon MD, Raimondo De Cristofaro MD, Esther Mairal MD, and Roser Mir PhD

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C) are the mainstay of treatment in von Willebrand disease (VWD). Real-world data on efficacy and safety of these pd-VWF/FVIII-C are required. To retrospectively evaluate the efficacy and safety of pd-VWF/FVIII-C (Fanhdi® and Alphanate®, Grifols) in clinical practice in Italy. A multicentric, observational, retrospective study at 10 Italian centers was conducted. Eligible patients diagnosed with inherited VWD (ISTH criteria) were treated with either Fanhdi® or Alphanate® for bleeding episodes, prevention of surgical bleeding and secondary long-term prophylaxis (SLTP) according to clinical practice with medical records collected from January 2007 to December 2019. Efficacy/safety of pd-VWF/FVIII-C was assessed according to FDA-agreed objective criteria following regulatory procedures. Fifty-seven patients (M/F: 21/36) were enrolled in the study with the following VWD types: VWD1 (n = 29, 52%), VWD2A (n = 10, 18%), VWD2B (n = 7, 12%), VWD2M (n = 2, 4%), VWD2N (n = 1, 2%), VWD2 unclassified (n = 1, 2%), and VWD3 (n = 7, 12%). These pd-VWF/FVIII-C were used to manage 58 bleeding episodes (n = 24 patients), 100 surgeries (n = 47 patients), and 7 SLTP (n = 6 patients). Global clinical efficacy with these pd-VWF/FVIII-C was reported to be excellent/good in 85% of bleeding episodes, 98% of surgeries, and 100% of SLTP. As far as safety, no adverse-drug-related episodes, immunogenic or thrombotic events were reported. This study confirmed that Fanhdi® and Alphanate® were effective and safe in the management of bleeding episodes, the prevention of bleeding during surgeries and for SLTP in Italian patients with inherited VWD.

Published
2024
Full Text
View/download PDF

7. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Author

Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger, Rachid Benhida, Lisa Kinget, Benoit Beuselinck, Cyril Ronco, Gilles Pagès, and Maeva Dufies

Subjects
Renal Cell Carcinoma, M2 tumor associated macrophages, Immunotherapies resistance, CXCR2 inhibitors, Nivolumab, Ipilimumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 inhibitors alongside immunotherapies. Methods We analyzed ELR + CXCL levels and their correlation with patient survival during immunotherapy. RCT001, a unique CXCR2 inhibitor, was examined for its mechanism of action, particularly its effects on human primary macrophages. We tested the synergistic impact of RCT001 in combination with immunotherapies in both mouse models of ccRCC and human ccRCC in the presence of human PBMC. Resuts Elevated ELR + CXCL cytokine levels were found to correlate with reduced overall survival during immunotherapy. RCT001, our optimized compound, acted as an inverse agonist, effectively inhibiting angiogenesis and reducing viability of primary ccRCC cells. It redirected M2-like macrophages without affecting M1-like macrophage polarization directed against the tumor. In mouse models, RCT001 enhanced the efficacy of anti-CTLA4 + anti-PD1 by inhibiting tumor-associated M2 macrophages and tumor-associated neutrophils. It also impacted the activation of CD4 T lymphocytes, reducing immune-tolerant lymphocytes while increasing activated natural killer and dendritic cells. Similar effectiveness was observed in human RCC tumors when RCT001 was combined with anti-PD-1 treatment. Conclusions RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.

Published
2024
Full Text
View/download PDF

8. Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial

Author

Billon, Emilien, Dalban, Cécile, Oudard, Stephane, Chevreau, Christine, Laguerre, Brigitte, Barthélémy, Philippe, Borchiellini, Delphine, Geoffrois, Lionnel, Negrier, Sylvie, Joly, Florence, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Rolland, Frederic, Priou, Frank, Mahammedi, Hakim, Tantot, Florence, Escudier, Bernard, Chabaud, Sylvie, Albiges, Laurence, and Gravis, Gwenaelle

Published
2024
Full Text
View/download PDF

13. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

Author

Carril-Ajuria, Lucia, Lavaud, Pernelle, Dalban, Cecile, Negrier, Sylvie, Gravis, Gwénaëlle, Motzer, Robert J., Chevreau, Christine, Tannir, Nizar M., Oudard, Stéphane, McDermott, David F., Laguerre, Brigitte, Hammers, Hans J., Barthelemy, Philippe, Plimack, Elizabeth R., Borchiellini, Delphine, Gross-Goupil, Marine, Jiang, Ruiyun, Lee, Chung-Wei, de Silva, Heshani, Rini, Brian I., Escudier, Bernard, and Albigès, Laurence

Published
2024
Full Text
View/download PDF

14. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study

Author

Mourey, Loïc, Rainho, Larissa Tames, Dalban, Cécile, Carril-Ajuria, Lucía, Negrier, Sylvie, Chevreau, Christine, Gravis, Gwenaëlle, Thibault, Constance, Laguerre, Brigitte, Barthelemy, Philippe, Borchiellini, Delphine, Gross-Goupil, Marine, Geoffrois, Lionnel, Rolland, Frederic, Thiery-Vuillemin, Antoine, Tantot, Florence, Chaput, Nathalie, Naigeon, Marie, Teixeira, Marcus, Escudier, Bernard, Flippot, Ronan, and Albiges, Laurence

Published
2024
Full Text
View/download PDF

16. A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA

Author

Colomba, Emeline, Jonas, Sarah Flora, Eymard, Jean-Christophe, Delva, Rémi, Brachet, Pierre Emmanuel, Neuzillet, Yann, Penel, Nicolas, Roubaud, Guilhem, Bompas, Emmanuelle, Mahammedi, Hakim, Longo, Raffaelle, Helissey, Carole, Barthélemy, Philippe, Borchiellini, Delphine, Hasbini, Ali, Priou, Franck, Saldana, Carolina, Voog, Eric, Narcisso, Bérangère, Ladoire, Sylvain, Berdah, Jean-François, Aisenfarb, Jean-Baptiste, Foulon, Stéphanie, and Fizazi, Karim

Published
2024
Full Text
View/download PDF

17. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Author

Bastick, Patricia, Sewak, Sanjeev, Tran, Ben, Pichler, Martin, Shariat, Shahrokh, Rottey, Sylvie, Schatteman, Peter, Schrijvers, Dirk, Verschaeve, Vincent, Vulsteke, Christof, Barros Leite Ferreira, Luiza Aleixo, de Santana Gomes Andrea Juliana, Pereira, Junior, Joao Antonio, Azevedo, Sergio, Bastos, Diogo, Borges, Giuliano, Dettino, Aldo, Antonio, Pires Luis, Luz, Murilo, Martins, Suelen, Mota, Jose Mauricio, Toledo, Joseane, Eigl, Bernhard, Finch, Daygen, Gingerich, Joel, Dong, Haiying, Huang, Jian, Jin, Jie, Pan, Hongming, Sun, Zhongquan, Tian, Ye, Wan, Ben, Wu, Bin, Xu, Ting, Xue, Wei, Zhou, Fangjian, Barthelemy, Philippe, Borchiellini, Delphine, Calcagno, Fabien, Carnot, Aurelien, Cornillon, Pierre, Delva, Remy, Emambux, Sheik, Houede, Nadine, Laguerre, Brigitte, Lauridant, Géraldine, Loriot, Yohann, Mahammedi, Hakim, Maillet, Denis, Pouessel, Damien, Roubaud, Guilhem, Schlurmann-Constans, Friederike, Tosi, Diego, Zanetta, Sylvie, Banek, Severine, Feyerabend, Susan, Kramer, Mario, Niegisch, Guenther, Nuhn, Philipp, Schnabel, Marco, Wuelfing, Christian, Baka, Sofia, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Harabolos, Karalis, Konstantinos, Kotsakis, Athanasios, Timotheadou, Eleni, Landherr, Laszlo, Mangel, Laszlo, Pe’er, Avivit, Levratovsky, Meital, Basso, Umberto, Battelli, Nicola, Cavo, Alessia, De Giorgi, Ugo, Doni, Laura, Galli, Luca, Gigante, Maria Olga, Guadalupi, Valentina, Maio, Michele, Milesi, Laura, Nolè, Franco, Scagliotti, Giorgio, Tortora, Giampaolo, Fukasawa, Satoshi, Harabayashi, Toru, Kamiya, Naoto, Kawahara, Takashi, Kawakita, Mutsushi, Matsubara, Nobunaki, Matsumoto, Kazumasa, Nishimura, Kazuo, Rikiya, Taoka, Shimizu, Nobuaki, Tagaki, Toshio, Kang, Taek Won, Kim, Jwa Hoon, Kim, SeHyun, Lee, Hyo Jin, Lee, Yun-Gyoo, Rha, Sun Young, Seo, Ho Kyung, Los, Maartje, Zurawski, Bogdan, Cortes, Paulo, Faustino, Catia, Vau, Nuno Sineiro, da Luz, Ricardo, Atduev, Vagif, Kirtbaya, Dmitry, Kopyltsov, Evgeny, Lykov, Aleksandr, Marat, Urmantsev, Orlov, Sergey, Penkov, Konstantin, Pirmagomedov, Albert, Semenov, Andrey, Varlamov, Sergey, Anguera, Georgia, Domenech, Montserrat, Girones, Regina, Gonzalez del Alba, Aranzazu, Milagro, Nuria Lainez, Luque, Raquel, Ortega, Esther Martínez, Mellado, Begoña, Méndez Vidal, María Jose, Fernandez, Esteban Nogales, Valderrama, Begoña Perez, Marín, Alvaro Pinto, Santander, Carmen, Huang, Yi-Hsiu, Su, Wen-Pin, Wu, Hung-Chan, Wu, WenJeng, Yu, Kai-Jie, Bilici, Ahmet, Goker, Erdem, Gumus, Mahmut, Karaoglu, Aziz, Kefeli, Umut, Köse, Fatih, Ozguroglu, Mustafa, Tural, Deniz, Turk, Haci, Yalcin, Suayib, Bondarenko, Igor, Khareba, Gennadii, Kidik, Yana, Lychkovskyy, Oleksandr, Sakalo, Valerii, Shevnia, Serghii, Stakhovskyy, Eduard, Bahl, Amit, Crabb, Simon, Powles, Thomas, Sankey, Peter, Sarwar, Mohammad, Benedetto, Pasquale, Burgess, Earle, Dawson, Nancy, Doshi, Gurjyot, Fleming, Mark, Maly, Joseph, Parikh, Mamta, Waterhouse, David, Siefker-Radtke, A.O., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Özgüroğlu, M., Valderrama, B.P., Laguerre, B., Basso, U., Triantos, S., Akapame, S., Kean, Y., Deprince, K., Mukhopadhyay, S., and Loriot, Y.

Published
2024
Full Text
View/download PDF

18. A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma

Author

Christopher Montemagno, Jérôme Durivault, Cécile Gastaldi, Maeva Dufies, Valérie Vial, Xingkang He, Damien Ambrosetti, Anna Kamenskaya, Sylvie Negrier, Jean‐Christophe Bernhard, Delphine Borchiellini, Yihai Cao, and Gilles Pagès

Subjects
alternative splicing, angio/lymphangiogenesis, renal cell carcinoma, resistance to antiangiogenics, VEGF, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The efficacy of anti‐angiogenic treatment by targeting VEGF/VEGF receptors in metastatic clear cell renal cell carcinoma (ccRCC) varies from patient to patient. Discovering the reasons behind this variability could lead to the identification of relevant therapeutic targets. Thus, we investigated the novel splice variants of VEGF that are less efficiently inhibited by anti‐VEGF/VEGFR targeting than the conventional isoforms. By in silico analysis, we identified a novel splice acceptor in the last intron of the VEGF gene resulting in an insertion of 23 bp in VEGF mRNA. Such an insertion can shift the open‐reading frame in previously described splice variants of VEGF (VEGFXXX), leading to a change in the C‐terminal part of the VEGF protein. Next, we analysed the expression of these alternatively spliced VEGF new isoforms (VEGFXXX/NF) in normal tissues and in RCC cell lines by qPCR and ELISA, and we investigated the role of VEGF222/NF (equivalent to VEGF165) in physiological and pathological angiogenesis. Our in vitro data demonstrated that recombinant VEGF222/NF stimulated endothelial cell proliferation and vascular permeability by activating VEGFR2. In addition, VEGF222/NF overexpression enhanced proliferation and metastatic properties of RCC cells, whereas downregulation of VEGF222/NF resulted in cell death. We also generated an in vivo model of RCC by implanting RCC cells overexpressing VEGF222/NF in mice, which we treated with polyclonal anti‐VEGFXXX/NF antibodies. VEGF222/NF overexpression enhanced tumour formation with aggressive properties and a fully functional vasculature, while treatment with anti‐VEGFXXX/NF antibodies slowed tumour growth by inhibiting tumour cell proliferation and angiogenesis. In a patient cohort from the NCT00943839 clinical trial, we investigated the relationship between plasmatic VEGFXXX/NF levels, resistance to anti‐VEGFR therapy and survival. High plasmatic VEGFXXX/NF levels correlated with shorter survival and lower efficacy of anti‐angiogenic drugs. Our data confirmed the existence of new VEGF isoforms that could serve as novel therapeutic targets in patients with RCC that are resistant to anti‐VEGFR therapy.

Published
2023
Full Text
View/download PDF

20. Targeted systematic evolution of an RNA platform neutralizing DNMT1 function and controlling DNA methylation

Author

Esposito, Carla L., Autiero, Ida, Sandomenico, Annamaria, Li, H., Bassal, Mahmoud A., Ibba, Maria L., Wang, Dongfang, Rinaldi, Lucrezia, Ummarino, Simone, Gaggi, Giulia, Borchiellini, Marta, Swiderski, Piotr, Ruvo, Menotti, Catuogno, Silvia, Ebralidze, Alexander K., Kortylewski, Marcin, de Franciscis, Vittorio, and Di Ruscio, Annalisa

Published
2023
Full Text
View/download PDF

21. Cicli inversi

Author

Borchiellini, Romano, Grisolia, Giulia, Lucia, Umberto, Borchiellini, Romano, Grisolia, Giulia, and Lucia, Umberto

Published
2022
Full Text
View/download PDF

22. I Sistemi Chiusi

Author

Borchiellini, Romano, Grisolia, Giulia, Lucia, Umberto, Borchiellini, Romano, Grisolia, Giulia, and Lucia, Umberto

Published
2022
Full Text
View/download PDF

23. I sistemi aperti

Author

Borchiellini, Romano, Grisolia, Giulia, Lucia, Umberto, Borchiellini, Romano, Grisolia, Giulia, and Lucia, Umberto

Published
2022
Full Text
View/download PDF

27. The compact genome of the sponge Oopsacas minuta (Hexactinellida) is lacking key metazoan core genes

Author

Sébastien Santini, Quentin Schenkelaars, Cyril Jourda, Marc Duchesne, Hassiba Belahbib, Caroline Rocher, Marjorie Selva, Ana Riesgo, Michel Vervoort, Sally P. Leys, Laurent Kodjabachian, André Le Bivic, Carole Borchiellini, Jean-Michel Claverie, and Emmanuelle Renard

Subjects
Microbiome, Symbiosis, Epithelium, Ciliogenesis, Signaling pathways, Transcription factors, Biology (General), QH301-705.5
Abstract

Abstract Background Explaining the emergence of the hallmarks of bilaterians is a central focus of evolutionary developmental biology—evodevo—and evolutionary genomics. For this purpose, we must both expand and also refine our knowledge of non-bilaterian genomes, especially by studying early branching animals, in particular those in the metazoan phylum Porifera. Results We present a comprehensive analysis of the first whole genome of a glass sponge, Oopsacas minuta, a member of the Hexactinellida. Studying this class of sponge is evolutionary relevant because it differs from the three other Porifera classes in terms of development, tissue organization, ecology, and physiology. Although O. minuta does not exhibit drastic body simplifications, its genome is among the smallest of animal genomes sequenced so far, and surprisingly lacks several metazoan core genes (including Wnt and several key transcription factors). Our study also provides the complete genome of a symbiotic Archaea dominating the associated microbial community: a new Thaumarchaeota species. Conclusions The genome of the glass sponge O. minuta differs from all other available sponge genomes by its compactness and smaller number of encoded proteins. The unexpected loss of numerous genes previously considered ancestral and pivotal for metazoan morphogenetic processes most likely reflects the peculiar syncytial tissue organization in this group. Our work further documents the importance of convergence during animal evolution, with multiple convergent evolution of septate-like junctions, electrical-signaling and multiciliated cells in metazoans.

Published
2023
Full Text
View/download PDF

28. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG—AFU 26 NIVOREN

Author

Guilhem-Ducléon, Guillemette, Dalban, Cécile, Negrier, Sylvie, Gravis, Gwenaelle, Laguerre, Brigitte, Chevreau, Christine, Oudard, Stéphane, Barthelemy, Philippe, Ladoire, Sylvain, Boughalem, Elouen, Borchiellini, Delphine, Linassier, Claude, Nenan, Soazig, Flippot, Ronan, Albiges, Laurence, and Goupil, Marine Gross

Published
2023
Full Text
View/download PDF

29. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Author

Fillitz, Michael, Knoebl, Paul, Meers, Stef, Amine, Ismail Mohamad, Gumulec, Jaromir, Hlusi, Antonin, Mayer, Jiri, Quittet, Philippe, Viallard, Jean-Francois, Betaneli, Magdana, Datikashvili-David, Irine, Iosava, Genadi, Makhaldiani, Levan, Rejto, Laszlo, Sharashenidze, Nino, Groepper, Stefanie, Röth, Alexander, Hamed, Aryan, Illes, Arpad, Carpenedo, Monica, Artoni, Andrea, Bocchia, Monica, Gamberi, Barbara, Borchiellini, Alessandra, Oliva, Esther Natalie, Patriarca, Andrea, Tomassetti, Simona, Miyakawa, Yoshitaka, Ando, Kiyoshi, Handa, Hiroshi, Katsutani, Shinya, Nishiwaki, Kaichi, Ito, Shoko, Ito, Tomoki, de Boer, Fransien, Jansen, A.J. Gerard, Ciepluch, Hanna, Fornagiel, Szymon, Grosicki, Sebastian, Soroka-Wojtaszko, Maria, Trelinski, Jacek, Bakirov, Bulat, Borisenkova, Elena, Volodicheva, Elena, Shatokhin, Yuri, Proydakov, Andrey, Alonso, Maria Aranzazu, Mingot-Castellano, María Eva, Sanchez-Gonzalez, Blanca, Valcarcel Ferreiras, David, Ayli, Meltem, Hacibekiroglu, Tuba, Demir, Ahmet Muzaffer, Nalçaci, Meliha, Sonmez, Mehmet, Tombak, Anil, Toprak, Selami Kocak, Turgut, Burhan, Vural, Filiz, Yagci, Munci, Altuntas, Fevzi, Turgut, Mehmet, Kaya, Emin, Romanyuk, Nataliya, McDonald, Vickie, Kazmi, Syed Rashid Saeed, Broome, Catherine, Cataland, Spero, Doshi, Ketan, Lentz, Steven R., Boxer, Michael, Rosenberg, Richard, Broome, Catherine M, Kuter, David J, Al-Samkari, Hanny, Bussel, James B, Godar, Marie, Ayguasanosa, Jaume, De Beuf, Kristof, Rodeghiero, Francesco, Michel, Marc, and Newland, Adrian

Published
2023
Full Text
View/download PDF

30. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study

Author

Baudry, Edwige, Naoun, Natacha, Auclin, Edouard, Saldana, Carolina, Barthelemy, Philippe, Geoffrois, Lionnel, Thibault, Constance, de Vries-Brilland, Manon, Borchiellini, Delphine, Maillet, Denis, Hirsch, Laure, Vauchier, Charles, Carril-Ajuria, Lucia, Colomba, Emeline, Bernard-Tessier, Alice, Escudier, Bernard, Flippot, Ronan, and Albigès, Laurence

Published
2023
Full Text
View/download PDF

31. Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy

Author

Giuseppe Palumbo, Piero Farruggia, Ugo Ramenghi, Giovanna Russo, Alessandra Borchiellini, Marco Spinelli, Carlo Dufour, Fiorina Giona, Saverio Ladogana, Marco Zecca, Silverio Perrotta, Andrea Pession, and Paola Giordano

Subjects
Pediatric immune thrombocytopenia, ITP, eltrombopag, second line, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

ABSTRACTBackground Immune thrombocytopenia (ITP) is the most common acquired bleeding disorder. In both children and adults, the primary goal of any therapeutic approach consists of cessation of bleeding and its prevention. Several options are currently available for first-line therapy in Europe, including corticosteroids and intravenous immunoglobulin (IVIg) infusion, which has a similar efficacy and safety profile in both the pediatric and adult populations. When second-line therapy is needed in the pediatric setting, current guidelines recommend eltrombopag as the drug of choice.Procedure The aim of this article is to summarize the available evidence and present real-life experience on eltrombopag as second-line therapy in pediatric patients with ITP, with a focus on dosing and response to therapy as well as its tapering and discontinuation.Results In our setting, eltrombopag is associated with good safety profile as well as promising efficacy; dose de-escalation was feasible in 94% of cases and often reached very low pro/kg dosage, with full discontinuation in 15% of cases. In daily practice, a standardized approach for discontinuation of eltrombopag in pediatric patients with ITP is still lacking. Herein, an easy-to-use scheme for tapering and discontinuation in candidate pediatric patients is proposed that proposes 25% dose reduction every four weeks.Conclusions In future management of pediatric ITP patients, it will be crucial to assess if thrombopoietin receptor agonists might be more effective in earlier phases of the disease and can modify the course of the disease.

Published
2023
Full Text
View/download PDF

33. Targeted systematic evolution of an RNA platform neutralizing DNMT1 function and controlling DNA methylation

Author

Carla L. Esposito, Ida Autiero, Annamaria Sandomenico, H. Li, Mahmoud A. Bassal, Maria L. Ibba, Dongfang Wang, Lucrezia Rinaldi, Simone Ummarino, Giulia Gaggi, Marta Borchiellini, Piotr Swiderski, Menotti Ruvo, Silvia Catuogno, Alexander K. Ebralidze, Marcin Kortylewski, Vittorio de Franciscis, and Annalisa Di Ruscio

Subjects
Science
Abstract

Here the authors generate an RNA-based platform to neutralize the major epigenetic player DNMT1. Using this targeted approach, aberrant DNA methylation in cancer can be corrected.

Published
2023
Full Text
View/download PDF

34. Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma

Author

Pignot, Géraldine, Ahallal, Youness, Lebacle, Cedric, Méjean, Arnaud, Long, Jean-Alexandre, Tillou, Xavier, Olivier, Jonathan, Bruyère, Franck, Charles, Thomas, Durand, Xavier, Lang, Hervé, Larre, Stéphane, Khene, Zine-Eddine, Bigot, Pierre, Doumerc, Nicolas, Ouzaid, Idir, Boissier, Romain, Nouhaud, François-Xavier, Albiges, Laurence, Bernhard, Jean-Christophe, Ingels, Alexandre, Borchiellini, Delphine, Kammerer-Jacquet, Solène, Rioux-Leclercq, Nathalie, Roupret, Morgan, Acosta, Oscar, De Crevoisier, Renaud, and Bensalah, Karim

Published
2023
Full Text
View/download PDF

36. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

Author

Velev, Maud, Dalban, Cécile, Chevreau, Christine, Gravis, Gwenaelle, Negrier, Sylvie, Laguerre, Brigitte, Gross-Goupil, Marine, Ladoire, Sylvain, Borchiellini, Delphine, Geoffrois, Lionnel, Joly, Florence, Priou, Frank, Barthelemy, Philippe, Laramas, Mathieu, Narciso, Berangère, Thiery-Vuillemin, Antoine, Berdah, Jean-François, Ferrari, Victoria, Dominique Thomas, Quentin, Mione, Cécile, Curcio, Hubert, Oudard, Stephane, Tantot, Florence, Escudier, Bernard, Chabaud, Sylvie, Albiges, Laurence, and Thibault, Constance

Published
2023
Full Text
View/download PDF

37. Temporal Structures in Positron Spectra and Charge-Sign Effects in Galactic Cosmic Rays

Author

M. Aguilar, G. Ambrosi, H. Anderson, L. Arruda, N. Attig, C. Bagwell, F. Barao, M. Barbanera, L. Barrin, A. Bartoloni, R. Battiston, N. Belyaev, J. Berdugo, B. Bertucci, V. Bindi, K. Bollweg, J. Bolster, M. Borchiellini, B. Borgia, M. J. Boschini, M. Bourquin, J. Burger, W. J. Burger, X. D. Cai, M. Capell, J. Casaus, G. Castellini, F. Cervelli, Y. H. Chang, G. M. Chen, G. R. Chen, H. Chen, H. S. Chen, Y. Chen, L. Cheng, H. Y. Chou, S. Chouridou, V. Choutko, C. H. Chung, C. Clark, G. Coignet, C. Consolandi, A. Contin, C. Corti, Z. Cui, K. Dadzie, F. D’Angelo, A. Dass, C. Delgado, S. Della Torre, M. B. Demirköz, L. Derome, S. Di Falco, V. Di Felice, C. Díaz, F. Dimiccoli, P. von Doetinchem, F. Dong, F. Donnini, M. Duranti, A. Egorov, A. Eline, F. Faldi, J. Feng, E. Fiandrini, P. Fisher, V. Formato, C. Gámez, R. J. García-López, C. Gargiulo, H. Gast, M. Gervasi, F. Giovacchini, D. M. Gómez-Coral, J. Gong, C. Goy, D. Grandi, M. Graziani, A. N. Guracho, S. Haino, K. C. Han, R. K. Hashmani, Z. H. He, B. Heber, T. H. Hsieh, J. Y. Hu, B. W. Huang, M. Ionica, M. Incagli, Yi Jia, H. Jinchi, G. Karagöz, S. Khan, B. Khiali, Th. Kirn, A. P. Klipfel, O. Kounina, A. Kounine, V. Koutsenko, D. Krasnopevtsev, A. Kuhlman, A. Kulemzin, G. La Vacca, E. Laudi, G. Laurenti, G. LaVecchia, I. Lazzizzera, H. T. Lee, S. C. Lee, H. L. Li, J. Q. Li, M. Li, Q. Li, Q. Y. Li, S. Li, S. L. Li, J. H. Li, Z. H. Li, J. Liang, M. J. Liang, C. H. Lin, T. Lippert, J. H. Liu, S. Q. Lu, Y. S. Lu, K. Luebelsmeyer, J. Z. Luo, S. D. Luo, Xi Luo, C. Mañá, J. Marín, J. Marquardt, T. Martin, G. Martínez, N. Masi, D. Maurin, T. Medvedeva, A. Menchaca-Rocha, Q. Meng, M. Molero, P. Mott, L. Mussolin, Y. Najafi Jozani, J. Negrete, R. Nicolaidis, N. Nikonov, F. Nozzoli, J. Ocampo-Peleteiro, A. Oliva, M. Orcinha, M. A. Ottupara, M. Palermo, F. Palmonari, M. Paniccia, A. Pashnin, M. Pauluzzi, S. Pensotti, V. Plyaskin, S. Poluianov, X. Qin, Z. Y. Qu, L. Quadrani, P. G. Rancoita, D. Rapin, A. Reina Conde, E. Robyn, I. Rodríguez-García, L. Romaneehsen, F. Rossi, A. Rozhkov, D. Rozza, R. Sagdeev, E. Savin, S. Schael, A. Schultz von Dratzig, G. Schwering, E. S. Seo, B. S. Shan, T. Siedenburg, G. Silvestre, J. W. Song, X. J. Song, R. Sonnabend, L. Strigari, T. Su, Q. Sun, Z. T. Sun, M. Tacconi, X. W. Tang, Z. C. Tang, J. Tian, Y. Tian, Samuel C. C. Ting, S. M. Ting, N. Tomassetti, J. Torsti, T. Urban, I. Usoskin, V. Vagelli, R. Vainio, M. Valencia-Otero, E. Valente, E. Valtonen, M. Vázquez Acosta, M. Vecchi, M. Velasco, J. P. Vialle, C. X. Wang, L. Wang, L. Q. Wang, N. H. Wang, Q. L. Wang, S. Wang, X. Wang, Yu Wang, Z. M. Wang, J. Wei, Z. L. Weng, H. Wu, Y. Wu, J. N. Xiao, R. Q. Xiong, X. Z. Xiong, W. Xu, Q. Yan, H. T. Yang, Y. Yang, A. Yelland, H. Yi, Y. H. You, Y. M. Yu, Z. Q. Yu, C. Zhang, F. Zhang, F. Z. Zhang, J. Zhang, J. H. Zhang, Z. Zhang, F. Zhao, C. Zheng, Z. M. Zheng, H. L. Zhuang, V. Zhukov, A. Zichichi, and P. Zuccon

Published
2023
Full Text
View/download PDF

38. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study

Author

Gaillard, Victor, Lhuillier, Albane, Bigot, Cécile, Pierard, Laure, Trensz, Philippe, Burgy, Mickael, Schuster, Caroline, Malouf, Gabriel, Fritsch, Aurélie, Lang, Hervé, Tricard, Thibault, Borchiellini, Delphine, Geoffrois, Lionnel, and Barthelemy, Philippe

Published
2022
Full Text
View/download PDF

39. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Author

Pignot, Géraldine, Thiery-Vuillemin, Antoine, Albigès, Laurence, Walz, Jochen, Lang, Hervé, Balssa, Loïc, Parier, Bastien, Geoffrois, Lionnel, Bensalah, Karim, Schlürmann, Friederike, Ladoire, Sylvain, Bigot, Pierre, Borchiellini, Delphine, Cassuto, Ophélie, Thibault, Constance, Ingels, Alexandre, Saldana, Véronique, Roubaud, Guilhem, Bernhard, Jean-Christophe, Gravis, Gwenaelle, and Barthélémy, Philippe

Published
2022
Full Text
View/download PDF

40. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Author

Bedke, Jens, Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dimitry, Pouliot, Frederic, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J., Borchiellini, Delphine, McDermott, Raymond S., Tamada, Satoshi, Nguyen, Allison Martin, Wan, Shuyan, Perini, Rodolfo F., Rhoda Molife, L., Atkins, Michael B., and Powles, Thomas

Published
2022
Full Text
View/download PDF

41. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

43. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Author

Vano, Yann-Alexandre, Elaidi, Réza, Bennamoun, Mostefa, Chevreau, Christine, Borchiellini, Delphine, Pannier, Diane, Maillet, Denis, Gross-Goupil, Marine, Tournigand, Christophe, Laguerre, Brigitte, Barthélémy, Philippe, Coquan, Elodie, Gravis, Gwenaëlle, Houede, Nadine, Cancel, Mathilde, Huillard, Olivier, Beuzeboc, Philippe, Fournier, Laure, Méjean, Arnaud, Cathelineau, Xavier, Doumerc, Nicolas, Paparel, Philippe, Bernhard, Jean-Christophe, de la Taille, Alexandre, Bensalah, Karim, Tricard, Thibault, Waeckel, Thibaut, Pignot, Géraldine, Braychenko, Elena, Caruso, Stefano, Sun, Cheng-Ming, Verkarre, Virginie, Lacroix, Guillaume, Moreira, Marco, Meylan, Maxime, Bougouïn, Antoine, Phan, Letuan, Thibault-Carpentier, Christelle, Zucman-Rossi, Jessica, Fridman, Wolf Herman, Sautès-Fridman, Catherine, and Oudard, Stéphane

Published
2022
Full Text
View/download PDF

44. The Buds of Oscarella lobularis (Porifera, Homoscleromorpha): A New Convenient Model for Sponge Cell and Evolutionary Developmental Biology.

Author

Rocher, Caroline, Vernale, Amélie, Fierro‐Constaín, Laura, Séjourné, Nina, Chenesseau, Sandrine, Marschal, Christian, Issartel, Julien, Le Goff, Emilie, Stroebel, David, Jouvion, Julie, Dutilleul, Morgan, Matthews, Cédric, Marschal, Florent, Brouilly, Nicolas, Massey‐Harroche, Dominique, Schenkelaars, Quentin, Ereskovsky, Alexander, Le Bivic, André, Renard, Emmanuelle, and Borchiellini, Carole

Abstract

The comparative study of the four non‐bilaterian phyla (Cnidaria, Placozoa, Ctenophora, and Porifera) provides insights into the origin of bilaterian traits. To complete our knowledge of the cell biology and development of these animals, additional non‐bilaterian models are needed. Given the developmental, histological, ecological, and genomic differences between the four sponge classes (Demospongiae, Calcarea, Homoscleromorpha, and Hexactinellida), we have been developing the Oscarella lobularis (Porifera, class Homoscleromorpha) model over the past 15 years. Here, we report a new step forward by inducing, producing, and maintaining in vitro thousands of clonal buds that now make possible various downstream applications. This study provides a full description of bud morphology, physiology, cells and tissues, from their formation to their development into juveniles, using adapted cell staining protocols. In addition, we show that buds have outstanding capabilities of regeneration after being injured and of re‐epithelization after complete cell dissociation. Altogether, Oscarella buds constitute a relevant all‐in‐one sponge model to access a large set of biological processes, including somatic morphogenesis, epithelial morphogenesis, cell fate, body axes formation, nutrition, contraction, ciliary beating, and respiration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.

Author

Fianchi, Luana, Bonanni, Matteo, Borchiellini, Alessandra, Valeri, Federica, Giuffrida, Gaetano, Grasso, Stephanie, Fozza, Claudio, Ponta, Michele, Tiscia, Giovanni L., Grandone, Elvira, Vianelli, Nicola, Dedola, Alessandra, Pirozzi, Teresa, Sacco, Monica, Lancellotti, Stefano, and De Cristofaro, Raimondo

Subjects
THROMBOTIC thrombocytopenic purpura, IDIOPATHIC thrombocytopenic purpura, VON Willebrand factor, HEALTH facilities, INTENSIVE care units
Abstract

Background/Objectives: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by the formation of anti-ADAMTS13 antibodies. Caplacizumab is approved for the treatment of acute episodes of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. Real-world data for the use of caplacizumab in Italy have been recently published by a limited number of centers located in the northern and middle regions of the country only. Methods: A total of 38 patients with iTTP were enrolled in the study in six Italian centers spread over the entire territory of the country. The patients' data were registered in eCRF. Results: All patients achieved normalization of platelet count (median 2.0 days, IQR: 2–4), within a time significantly shorter than in the absence of caplacizumab, as previously reported in other studies. As to the secondary aims, patients treated with caplacizumab had a few exacerbations (4/38 (10.5%)) and relapses (2/38, 5.3%). No deaths or refractoriness were observed in these patients. The total length of hospitalization was 12 days (IQR: 9–18) and only one patient required 2 days of stay in the intensive care unit. Interestingly, when caplacizumab was initiated within the first 3 days, the plasma exchange (PEX) duration was 9 days (IQR: 8–10), which was significantly lower than those reported in previous studies conducted in the absence of caplacizumab. No severe adverse event was described in the caplacizumab-treated patients. Conclusions: Caplacizumab reduced exacerbations and refractoriness compared with previously reported standard-of-care regimens. When administered in association with PEX and immunosuppressive therapy, caplacizumab provided rapid normalization of platelet count, which was responsible for lower overall hospitalization time, ICU stay, lower exacerbations and relapses compared to previously reported outcomes of studies carried out without caplacizumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Author

Parnis, Francis, Joshua, Anthony M., Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Gurney, Howard, Ferguson, Thomas, Van Bruwaene, Siska, Luyten, Daisy, Schatteman, Peter, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Seront, Emmanuel, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Pinczowski, Hélio, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Fizazi, Karim, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Eymard, Jean-Christophe, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Leibowitz-Amit, Raya, Mermershtain, Wilmosh, Rouvinov, Keren, Peer, Avivit, Kovel, Svetlana, Sella, Avishay, Lolkema, Martijn P., van den Eertwegh, Alfonsus J.M., Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Kim, Choung-Soo, Choi, Young-Deuk, Chung, Byung-Ha, Gafanov, Rustem A., Kopyltsov, Evgeniy, Usynin, Evgeny A., Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Estellés, David Lorente, Sarrió, Regina Gironés, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Ståhl, Olof, Chiang, Po-Hui, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Wu, Hsi-Chin, Lu, Yu-Chuan, Attard, Gerhardt, Khoo, Vincent, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Sieber, Paul R., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Flaig, Thomas W., Emamekhoo, Hamid, Pinski, Jacek K., Kalebasty, Arash Rezazadeh, Maly, Joseph J., Moon, Helen, Smith, Matthew R, Scher, Howard I, Lara, Primo N, Jr, Yu, Evan Y, George, Daniel J, Chi, Kim N, Danila, Daniel C, Mason, Gary E, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, and Lopez-Gitlitz, Angela

Published
2022
Full Text
View/download PDF

48. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Author

Necchi, Andrea, Loriot, Yohann, Park, Se Hoon, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Burgess, Earle, Rezazadeh, Arash, Siefker-Radtke, Arlene, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Lee, Hyo Jin, Shin, Dong Bok, Cebotaru, Cristina, Duran, Ignacio, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Hainsworth, John, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Klotz, Theodor, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, Jain, Sharad, Zakharia, Yousef, Siefker-Radtke, Arlene O, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Tagawa, Scott T, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, and O'Hagan, Anne

Published
2022
Full Text
View/download PDF

49. Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group

Author

M. Guerin, C. Miran, E. Colomba, M. Cabart, T. Herrmann, S. Pericart, D. Maillet, Y. Neuzillet, A. Deleuze, E. Coquan, M. Laramas, C. Thibault, B. Abbar, B. Mesnard, D. Borchiellini, C. Dumont, E. Boughalem, JL. Deville, M. Cancel, C. Saldana, A. Khalil, G. Baciarello, A. Flechon, J. Walz, and G. Gravis

Subjects
retrospective, urachal cancer, multicentric, urachus, rare disease, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

IntroductionUrachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome, the most common histological subtype of UrC is adenocarcinoma. UrC develops from an embryonic remnant, and is frequently diagnosed in advanced stage with poor prognosis. The treatment is not standardized, and based only on case reports and small series. This large retrospective multicentric study was conducted by the French Genito-Urinary Tumor Group to gain a better understanding of UrC.Material and Methodsdata has been collected retrospectively on 97 patients treated at 22 French Cancer Centers between 1996 and 2020.ResultsThe median follow-up was 59 months (range 44-96). The median age at diagnosis was 53 years (range 20-86), 45% were females and 23% had tobacco exposure. For patients with localized disease (Mayo I-II, n=46) and with lymph-node invasion (Mayo III, n=13) median progression-free-survival (mPFS) was 31 months (95% CI: 20-67) and 7 months (95% CI: 6-not reached (NR)), and median overall survival (mOS) was 73 months (95% CI: 57-NR) and 22 months (95% CI: 21-NR) respectively. For 45 patients with Mayo I-III had secondary metastatic progression, and 20 patients were metastatic at diagnosis. Metastatic localization was peritoneal for 54% of patients. Most patients with localized tumor were treated with partial cystectomy, with mPFS of 20 months (95% CI: 14-49), and only 12 patients received adjuvant therapy. Metastatic patients (Mayo IV) had a mOS of 23 months (95% CI: 19-33) and 69% received a platin-fluorouracil combination treatment.ConclusionUrC is a rare tumor of the bladder where patients are younger with a higher number of females, and a lower tobacco exposure than in standard urothelial carcinoma. For localized tumor, partial cystectomy is recommended. The mOS and mPFS were low, notably for patients with lymph node invasion. For metastatic patients the prognosis is poor and standard therapy is not well-defined. Further clinical and biological knowledge are needed.

Published
2023
Full Text
View/download PDF

50. Properties of Cosmic-Ray Sulfur and Determination of the Composition of Primary Cosmic-Ray Carbon, Neon, Magnesium, and Sulfur: Ten-Year Results from the Alpha Magnetic Spectrometer

Author

M. Aguilar, L. Ali Cavasonza, B. Alpat, G. Ambrosi, L. Arruda, N. Attig, C. Bagwell, F. Barao, L. Barrin, A. Bartoloni, S. Başeğmez-du Pree, R. Battiston, N. Belyaev, J. Berdugo, B. Bertucci, V. Bindi, K. Bollweg, J. Bolster, M. Borchiellini, B. Borgia, M. J. Boschini, M. Bourquin, E. F. Bueno, J. Burger, W. J. Burger, X. D. Cai, M. Capell, J. Casaus, G. Castellini, F. Cervelli, Y. H. Chang, G. M. Chen, G. R. Chen, H. Chen, H. S. Chen, Y. Chen, L. Cheng, H. Y. Chou, S. Chouridou, V. Choutko, C. H. Chung, C. Clark, G. Coignet, C. Consolandi, A. Contin, C. Corti, Z. Cui, K. Dadzie, A. Dass, C. Delgado, S. Della Torre, M. B. Demirköz, L. Derome, S. Di Falco, V. Di Felice, C. Díaz, F. Dimiccoli, P. von Doetinchem, F. Dong, F. Donnini, M. Duranti, A. Egorov, A. Eline, F. Faldi, J. Feng, E. Fiandrini, P. Fisher, V. Formato, C. Gámez, R. J. García-López, C. Gargiulo, H. Gast, M. Gervasi, F. Giovacchini, D. M. Gómez-Coral, J. Gong, C. Goy, V. Grabski, D. Grandi, M. Graziani, A. N. Guracho, S. Haino, K. C. Han, R. K. Hashmani, Z. H. He, B. Heber, T. H. Hsieh, J. Y. Hu, B. W. Huang, M. Incagli, W. Y. Jang, Yi Jia, H. Jinchi, G. Karagöz, B. Khiali, G. N. Kim, Th. Kirn, O. Kounina, A. Kounine, V. Koutsenko, D. Krasnopevtsev, A. Kuhlman, A. Kulemzin, G. La Vacca, E. Laudi, G. Laurenti, G. LaVecchia, I. Lazzizzera, H. T. Lee, S. C. Lee, H. L. Li, J. Q. Li, M. Li, Q. Li, Q. Y. Li, S. Li, S. L. Li, J. H. Li, Z. H. Li, J. Liang, M. J. Liang, C. H. Lin, T. Lippert, J. H. Liu, S. Q. Lu, Y. S. Lu, K. Luebelsmeyer, J. Z. Luo, S. D. Luo, Xi Luo, F. Machate, C. Mañá, J. Marín, J. Marquardt, T. Martin, G. Martínez, N. Masi, D. Maurin, T. Medvedeva, A. Menchaca-Rocha, Q. Meng, V. V. Mikhailov, M. Molero, P. Mott, L. Mussolin, J. Negrete, N. Nikonov, F. Nozzoli, J. Ocampo-Peleteiro, A. Oliva, M. Orcinha, M. A. Ottupara, M. Palermo, F. Palmonari, M. Paniccia, A. Pashnin, M. Pauluzzi, S. Pensotti, V. Plyaskin, S. Poluianov, X. Qin, Z. Y. Qu, L. Quadrani, P. G. Rancoita, D. Rapin, A. Reina Conde, E. Robyn, L. Romaneehsen, A. Rozhkov, D. Rozza, R. Sagdeev, S. Schael, A. Schultz von Dratzig, G. Schwering, E. S. Seo, B. S. Shan, T. Siedenburg, J. W. Song, X. J. Song, R. Sonnabend, L. Strigari, T. Su, Q. Sun, Z. T. Sun, M. Tacconi, X. W. Tang, Z. C. Tang, J. Tian, Y. Tian, Samuel C. C. Ting, S. M. Ting, N. Tomassetti, J. Torsti, T. Urban, I. Usoskin, V. Vagelli, R. Vainio, M. Valencia-Otero, E. Valente, E. Valtonen, M. Vázquez Acosta, M. Vecchi, M. Velasco, J. P. Vialle, C. X. Wang, L. Wang, L. Q. Wang, N. H. Wang, Q. L. Wang, S. Wang, X. Wang, Yu Wang, Z. M. Wang, J. Wei, Z. L. Weng, H. Wu, Y. Wu, J. N. Xiao, R. Q. Xiong, X. Z. Xiong, W. Xu, Q. Yan, H. T. Yang, Y. Yang, I. I. Yashin, A. Yelland, H. Yi, Y. H. You, Y. M. Yu, Z. Q. Yu, M. Zannoni, C. Zhang, F. Zhang, F. Z. Zhang, J. Zhang, J. H. Zhang, Z. Zhang, F. Zhao, C. Zheng, Z. M. Zheng, H. L. Zhuang, V. Zhukov, A. Zichichi, and P. Zuccon

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results